P57 HER-2/neu over-expression among Filipino patients with breast cancer: a 10 year review

Sanchez, Marine; Yeo, A.; Gorospe, Charity; Li, R.K.; Dy, Christine J.; Luna, Gidsela; Caguioa, Priscilla B.

doi:10.1016/s0960-9776(07)70122-4

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We selected 22 studies (see Table 1 ), including 17 publications 10-26 and 5 conference abstracts, 27-31 for further review. For Malaysia 30 , 31 and the Philippines, 29 only conference abstracts met our selection criteria.…”

Section: Resultsmentioning

confidence: 99%

“…However, although some categorized both IHC2+ and IHC3+ staining as positive, 12 , 17 , 18 , 20 , 21 others categorized only IHC3+ staining as positive. 11 , 14 , 25 , 29 Recent guidelines that were published jointly by the American Society for Clinical Oncology and the College of American Pathologists (ASCO/CAP) recommend reporting IHC2+ and IHC3+ staining separately and confirming the ErbB2 status of IHC2+ tumors by FISH. 9 These recommendations are based on the poor concordance between IHC2+ staining and gene amplification by FISH.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The prevalence and assessment of ErbB2‐positive breast cancer in Asia

Tan

Han

et al. 2010

Cancer

View full text Add to dashboard Cite

Overexpression of the epidermal growth factor receptor-related gene ErbB2 occurs in 18% to 25% of patients with breast cancer in Western countries and is associated with a poor prognosis. The prevalence of ErbB2-positive tumors in Asia is unclear, partly because data are limited. The objective of this review was to summarize the reported prevalence of ErbB2-positive tumors from a large sample of Asian patients and to examine ErbB2 assessment methods in Asia. From searches of MEDLINE, local language journals, and local and international conference proceedings as well as locoregional breast cancer experts' recommendations, the authors selected up to 5 studies each from India, Korea, Malaysia, the Philippines, Singapore, Taiwan, and Thailand that reported ErbB2 results based on assessment with immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH). The reported prevalence of ErbB2-positive tumors in 22 studies on 24,671 patients, of whom 14,398 patients were assessed for ErbB2 status, varied widely (range, 6%-65%) as did the assessment methods used. Most studies (n = 21) used IHC to assess ErbB2 status, but definitions for positivity varied. When robust assessment methods were used, the median prevalence was 19% based on strong IHC staining (IHC3+; n = 9812 patients) and 25% based on FISH (n = 681 patients). Data on the prevalence of ErbB2-positive breast cancer in Asia are limited. The current survey indicated that the prevalence in Asia may be similar to that in Western countries; thus, up to 1 in 4 Asian patients with breast cancer potentially could benefit from ErbB2-targeted treatment. A standard, reliable ErbB2 assessment method available to patients across Asia is urgently required. Cancer 2010;116:5348–57. © 2010 American Cancer Society.

show abstract

Section: Resultsmentioning

confidence: 99%